Accordingly, Bemcentinib (R428), a selective Axl inhibitor, is currently in phase I/II clinical trials of Acute Myeloid Leukemia (AML), glioblastoma and malignant mesothelioma and has completed phase II clinical trials in patients with non-small cell lung cancer (NCT02424617) or metastatic pancreatic cancer (NCT03649321). This evidence concerns the gene AXL and acute myeloid leukemia.